Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials Untreated ...

For patients with B-cell lymphoma, the addition of Revlimid to standard R-CHOP did not improve progression-free survival nor event-free survival. The addition of Revlimid (lenalidomide) to standard ...

Dexamethasone pretreatment reduces GI complications in DLBCL patients with GI involvement without compromising efficacy. The study showed no significant differences in response rates or survival ...

- Preliminary safety and efficacy data from Phase 1b firstMIND trial in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) presented today - Also presented today: Long-term subgroup ...

A BTK inhibitor combined with standard R-CHOP produced rapid, PET-defined complete remission in high-risk DLBCL-type Richter syndrome with TP53 deletion. Delaying ibrutinib until cycle 2 was used as a ...

Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...

Compared with rituximab plus CHOP, CHOP-radioimmunotherapy demonstrated superior 15-year PFS (47 vs 34%). HealthDay News — For patients with untreated, advanced ...

Please provide your email address to receive an email when new articles are posted on . The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly ...

The combination of Epkinly and R-mini-CHOP showed a 93% ORR and 86% CR rate in elderly DLBCL patients. At two years, 79% of patients remained in complete response, with a 76% progression-free survival ...